The latest issue of the Pulmonary Hypertension Association’s member magazine explores “Pathways to Hope” – through support groups, specialized PH clinics, self-advocacy, new medications and more.

The fall 2022 Pathlight cover story examines three promising new treatments for pulmonary arterial hypertension and how PAH treatments work in the body. The three medications target different biological process than currently available treatments. One of the new treatments could be approved by the Food and Drug Administration as early as 2023.

Our patient stories also embody hope. In our volunteer spotlight, New Orleanian Linda Gates shares tips for traveling with pulmonary hypertension. Although she thought her traveling days were over after her PH diagnosis, a PHA support group gave her the hope and confidence to continue. Today, she leads that support group. And she’s still traveling.

Similarly, our donor spotlight focuses on the comeback of a former college basketball coach. During the first two years of the pandemic, Barron Honea was perplexed by his shortness of breath and failing health. He repeatedly tested negative for COVID and didn’t connect his symptoms with the rare disease his cousin had died from. Eventually, he discovered a PHA-accredited PH Care Center, a diagnosis — and treatment that has him feeling like himself again. We’ve shared parts of Coach Bear’s story in PHA News and a recent fundraising campaign, but the full story is available only in Pathlight.

The fall issue of Pathlight also features the story of Donna Peratino. Like many people with PH, Peratino experienced the trial-and-error struggle to find the right medication. After she found a treatment that worked, her insurance company wanted to cover only the generic version, which didn’t work as well for her. She gives hope to others similar situations with tips to fight the insurance company – and win.

In addition to patients, several PH health care professionals share information and tips. Lindsay “Shelley” Forbes, MD, discusses the connection between PH and interstitial lung diseases for Pulmonary Fibrosis Awareness Month. Gillian Leung, PharmD, BCCP, and Kelly Schmit, MGCS, LCGC, share how they got interested in PH and what they do in their professional roles. Both will be speaking at PHA’s PH Professional Network Symposium, Sept. 28-30.

These inspiring stories of people with PH, the promise of new treatments and other pathways to hope can be found only in Pathlight magazine, PHA’s quarterly member magazine. Join or renew your PHA membership to access this issue online or receive a free copy by mail.